Lanreotide

Introduction Overview

Generic Name

lanreotide

Brand Name

Somatuline Depot

Dosage Form

Deep subcutaneous injection (long-acting depot formulation)

Drug Class

Somatostatin and somatostatin analogs

Pharmacokinetics

Absorption:
Lanreotide administered as Somatuline Depot is formulated as a long-acting deep subcutaneous injection designed for slow release and prolonged absorption. Following injection, lanreotide is slowly absorbed into the systemic circulation over several weeks, permitting dosing intervals typically of 4 weeks. The absorption kinetics provide a sustained plasma concentration which allows suppression of growth hormone and other target peptides with reduced injection frequency. Variability in absorption may occur due to injection site, tissue perfusion, and patient-specific factors.

Distribution:
Lanreotide distributes primarily in the extracellular fluid compartment with limited tissue penetration due to its peptide nature. The volume of distribution is relatively low, consistent with plasma protein binding and limited crossing of cellular membranes. Lanreotide exhibits high affinity for somatostatin receptors located on neuroendocrine tissues, target tumors, and the pituitary gland. This receptor binding contributes to its therapeutic effects by targeting tumor cells and inhibiting hormone secretion.

Metabolism:
Lanreotide is metabolized primarily by proteolytic degradation into smaller inactive peptides and amino acids. Unlike small molecule drugs, it does not undergo significant hepatic cytochrome P450 metabolism. The enzymatic breakdown occurs mainly in tissues and plasma through peptidase activity. There is minimal involvement of hepatic enzymes, thus it is less susceptible to common drug interactions mediated by CYP450 enzymes.

Elimination:
The metabolites of lanreotide are eliminated primarily via the renal route. Small peptides generated from proteolysis are filtered and excreted in urine. The elimination half-life of lanreotide after depot administration is extended, typically averaging around 30 days, which supports the once-monthly dosing schedule. Renal impairment can alter elimination kinetics, necessitating monitoring in patients with significant kidney dysfunction. No significant biliary excretion occurs. Clinical studies show steady elimination supporting sustained plasma levels and efficacy with monthly dosing.

Dosage Forms

Available Dosage Forms:
- Deep subcutaneous injection (long-acting depot formulation) provided as prefilled syringes or autoinjectors containing lanreotide acetate in concentrations suitable for dosing at 60 mg, 90 mg, and 120 mg.
- Somatuline Depot is formulated as a viscous gel for slow release upon injection.

Dosages for Adults and Adolescents:
- Acromegaly: Initial dose of 90 mg administered by deep subcutaneous injection every 4 weeks for 3 months. Dose adjustments are made after this period based on growth hormone and IGF-1 levels.
- Neuroendocrine Carcinomas (GEP-NETs): 120 mg by deep subcutaneous injection every 4 weeks to improve progression-free survival.
- Carcinoid Syndrome: 120 mg by deep subcutaneous injection every 4 weeks to reduce symptoms and frequency of rescue short-acting therapy.
Doses may be modified based on clinical response and tolerability. Elderly patients typically do not require dose adjustments.

Specific Patient Populations:
- Elderly: No dose adjustment required.
- Hepatic or Renal Impairment: Caution advised; dose adjustments may be necessary based on clinical evaluation as metabolism and elimination may be affected.
- Pregnancy and Lactation: Safety is not established; use only if clearly needed. Breastfeeding is not recommended during therapy and for at least 6 months after last dose.
- Patients with diabetes may require close monitoring and adjustment of hypoglycemic agents due to the drug's effects on insulin and glucose regulation.

Mechanism Of Action

Lanreotide, the active agent in Somatuline Depot, is a synthetic cyclic octapeptide analog of the natural hormone somatostatin. It mimics somatostatin’s inhibitory effects on hormone secretion by binding with high affinity to somatostatin receptors, predominantly subtypes 2 and 5 (SSTR2 and SSTR5), which are expressed on neuroendocrine cells, pituitary somatotrophs, and various tumor cells. Upon receptor binding, lanreotide activates intracellular signaling cascades that inhibit adenylyl cyclase activity, leading to reduced cyclic AMP levels and subsequent suppression of hormone exocytosis.

Cellular pathways affected include inhibition of calcium influx and modulation of potassium channels, resulting in decreased secretion of growth hormone (GH), insulin, glucagon, and other peptides involved in digestive processes. This leads to decreased circulating levels of insulin-like growth factor 1 (IGF-1), a critical mediator of acromegaly symptoms. In neuroendocrine tumors, this receptor-mediated inhibition reduces tumor hormone hypersecretion and may exert antiproliferative effects by inducing cell cycle arrest and apoptosis.

Biochemically, the drug interferes with secretory granule release and inhibits factors promoting angiogenesis and cellular proliferation, contributing to symptom control and disease stabilization. Comparative studies show lanreotide shares a similar mechanism to other somatostatin analogs such as octreotide but has unique pharmacokinetic properties that allow for extended dosing intervals.

Clinical trials and research evidence demonstrate that repeated administration of lanreotide significantly lowers GH and IGF-1 levels in acromegalic patients, reduces carcinoid syndrome symptoms such as flushing and diarrhea, and prolongs progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors. This molecular mechanism is central to its therapeutic efficacy and favorable safety profile.

Pharmacological Actions

Inhibits secretion of growth hormone by binding to somatostatin receptors in the pituitary gland.
Suppresses insulin and glucagon release from pancreatic islets, modulating glucose metabolism.
Reduces gastrointestinal hormone secretion, improving symptoms in carcinoid syndrome.
Exerts antiproliferative effects on neuroendocrine tumor cells by inducing apoptosis and cell cycle arrest.
Decreases secretion of vasoactive intestinal peptides, thus reducing diarrhea and flushing.
Lowers circulating insulin-like growth factor 1 (IGF-1) levels, key in acromegaly management.
Modulates neurotransmitter release and affects gastrointestinal motility and fluid secretion.
Acts as an antiangiogenic agent by inhibiting factors involved in tumor blood vessel formation.
Suppresses hormone-mediated paraneoplastic symptoms in neuroendocrine tumors.
Stabilizes tumor growth and improves progression-free survival in unresectable neuroendocrine tumors.
Inhibits secretion of thyroid-stimulating hormone (TSH) in certain conditions.
Decreases secretion and activity of digestive enzymes, potentially reducing pancreatic stimulation.
Minimal immunogenicity due to peptide nature and human somatostatin resemblance.

Therapeutic Or Clinical Uses

Treatment of acromegaly in adults where surgery or radiotherapy has failed or is not possible.
Management of carcinoid syndrome to control flushing and diarrhea associated with neuroendocrine tumors.
Treatment of unresectable, well or moderately differentiated metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival.
Symptomatic control of hormone secretion in neuroendocrine tumors of the pancreas and digestive tract.
Adjunct therapy in patients with neuroendocrine tumors for whom localized treatment is inadequate.
Reduction of need for short-acting somatostatin analog rescue medication in carcinoid syndrome.
Potential use in other somatostatin receptor-positive tumors based on emerging clinical trial data.
Management of symptoms related to hormone hypersecretion such as sweating, diarrhea, and abdominal pain.
Used post-failure of surgical and radiation treatments in acromegalic patients to normalize growth hormone and IGF-1 levels.
May reduce tumor burden and hormone secretion in neuroendocrine carcinoma cases.
Palliative treatment to improve quality of life by reducing tumor-secreted hormone-related symptoms.
Off-label uses under clinical evaluation include control of refractory diarrhea and endocrine tumors beyond standard indications.

Side Or Adverse Effects

Injection site reactions including pain, itching, nodules, or hard lumps.
Gastrointestinal disturbances: nausea, vomiting, diarrhea, and abdominal pain.
Headache and dizziness frequently reported during therapy.
Muscle or joint pain and general asthenia (weakness).
Hypoglycemia symptoms such as headache, sweating, hunger, irritability, dizziness, and rapid heart rate due to insulin suppression.
Hyperglycemia manifestations including increased thirst, frequent urination, dry mouth, and fruity breath odor.
Signs and symptoms of gallbladder disease including biliary colic, nausea, fever, chills, and jaundice.
Underactive thyroid symptoms: fatigue, dry skin, hair thinning, weight gain, puffiness, and cold intolerance.
Rare allergic reactions such as urticaria, swelling of face/lips/tongue, and difficulty breathing.
Cardiac adverse effects including chest pain, slow heartbeats, shortness of breath, syncope, and palpitations.
Neuropsychiatric symptoms including confusion, memory problems, and lethargy.
Potential for gallstones formation associated with decreased motility of the gallbladder.
Transient increases in liver enzymes reported in some patients.
Injection site granuloma formation reported with extended use.
Rare cases of pancreatitis and hepatic toxicity, requiring monitoring.

Precautions

Use caution in patients with pre-existing gallbladder disease due to risk of biliary complications.
Monitor blood glucose levels closely in patients with diabetes; dosage adjustments of antidiabetic medications may be necessary.
Assess liver and renal function prior to and during treatment; adjust therapy accordingly.
Screen for thyroid dysfunction periodically, monitor thyroid hormonal values.
Avoid use in patients with known hypersensitivity to lanreotide or any component of the formulation.
Pregnant women should only use if clearly needed; drug effects on fetal development are unknown.
Avoid breastfeeding during therapy and for at least six months following the last dose.
Monitor cardiac function as lanreotide may influence heart rate and conduction.
Patients should inform healthcare providers about all concomitant medications to prevent unforeseen interactions.
Use with caution in patients with severe cardiac disease or arrhythmias.
Monitor for signs of nutrient malabsorption due to inhibitory effects on gastrointestinal hormones.
Adjust dose in elderly patients based on clinical response and tolerability, though standard doses are generally safe.
Advise patients to report any symptoms of hypoglycemia or hyperglycemia immediately.
Regularly assess symptom control and hormone levels to evaluate therapeutic effectiveness.
Consider risk-benefit balance in patients with multiple comorbidities.

Warnings

Potential for serious allergic reactions; immediate medical attention required if symptoms such as hives or swelling occur.
May cause disturbances in glucose metabolism leading to hypoglycemia or hyperglycemia.
Risk of gallbladder complications including cholelithiasis and cholecystitis; monitor patients for biliary symptoms.
Cardiac effects including bradycardia and conduction abnormalities necessitate monitoring in susceptible patients.
Not recommended during breastfeeding; may affect fertility in women.
Avoid abrupt discontinuation without medical advice due to risk of symptom exacerbation.
Use cautiously in patients with thyroid disorders due to potential for hypothyroidism.
Interactions with drugs that affect heart rate (e.g., beta blockers) can augment cardiac side effects.
Dose may need adjustment when used concomitantly with immunosuppressants like cyclosporine.
Patients should be closely observed for worsening of neuroendocrine symptoms or tumor progression.
Hypersensitivity reactions have been reported, including injection site reactions that may worsen.
Ensure adherence to dosing schedule to maintain steady therapeutic plasma levels.
Patients should carry identification regarding their therapy due to potential side effects impacting emergency care.
Monitor liver function tests as rare hepatotoxicity cases may occur.
Promptly report any signs of severe abdominal pain or jaundice to healthcare providers.

Contraindication

Known allergy or hypersensitivity to lanreotide or any excipients in Somatuline Depot.
Severe hypersensitivity reactions to other somatostatin analogs contraindicate use.
Patients with active gallbladder infection or severe gallbladder disease may be contraindicated without careful risk assessment.
Not recommended for use in breastfeeding women.
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Patients with acute pancreatitis or severe gastrointestinal diseases without appropriate monitoring.
Severe bradycardia or advanced conduction disturbances unless medically supervised.
Known intolerance to peptides or similar injectable drugs.
Patients with known severe renal impairment may require contraindication pending risk-benefit determination.
Those with decompensated liver failure should avoid lanreotide unless essential.
Contraindicated in individuals who have had serious adverse dermatologic reactions to the drug.
Not indicated for children and adolescents due to lack of established safety and efficacy.
Use is contraindicated in patients with untreated hypothyroidism until condition is stable.
Contraindicated when concomitant use with drugs that severely depress cardiac conduction without appropriate monitoring.
Patients with difficulty tolerating subcutaneous injections due to local reactions or allergies.

Drug Interactions

May interact with insulin and oral hypoglycemic agents, necessitating dosage adjustments due to alterations in glucose metabolism.
Concomitant use with cyclosporine may require monitoring and dose modification as lanreotide can alter cyclosporine levels.
Beta-blockers and other heart rate lowering agents may exacerbate bradycardia or conduction abnormalities.
Potential to affect absorption and metabolism of other concomitant drugs by slowing gastrointestinal motility.
Possible interaction with bromocriptine, thus monitoring for additive effects on hormone suppression is advised.
Lanreotide may alter the pharmacokinetics of immunosuppressant medications, requiring careful therapeutic drug monitoring.
No significant CYP450 enzyme-mediated interactions, but vigilance advised with drugs metabolized via alternative pathways.
May impact absorption of fat-soluble vitamins due to decreased pancreatic enzyme secretion.
Combination with other somatostatin analogs or drugs that suppress gastrointestinal hormones should be avoided.
Caution when used with QT-prolonging drugs due to additive cardiac conduction effects.
Use with agents affecting thyroid function (levothyroxine) requires monitoring as lanreotide can cause hypothyroidism.
Potential to modify the effects of antihypertensive medications requiring blood pressure monitoring.
Interactions with opioid analgesics may modify gastrointestinal motility and symptom profile.
Drugs affecting renal function should be monitored as lanreotide metabolites are renally excreted.
Herbal supplements and vitamins should be reported as their interaction profile is not well characterized.

Preparations Of The Drug

Somatuline Depot provided as lanreotide acetate formulated for deep subcutaneous injection.
Prefilled syringes containing lanreotide concentrations of 60 mg, 90 mg, and 120 mg doses.
Supplied as a viscous gel formulation enabling slow release over 4 weeks.
Single-use sterile prefilled syringes with attached safety needles for outpatient or clinical administration.
Requires refrigeration at 2°C - 8°C and should be brought to room temperature before injection.
Supplied with specific administration instructions to ensure proper deep subcutaneous injection technique.
Available in packaging designed for monthly dosing schedules.
No oral or intravenous formulations currently available; only approved subcutaneous depot injections.
No preservatives included; strictly for single-use to avoid infection risk.
Vials or cartridges are not commonly used; the product is provided mostly as ready-to-use prefilled syringes.
Manufacturer instructions include careful handling to prevent needle stick injuries.
Disposal of used syringes must follow biohazard protocols.
Labeling indicates indications, dosing schedules, and storage requirements.
Stability data support shelf life of several months under recommended storage conditions.
Parenteral route limits self-administration in some settings but specialized autoinjectors are under development.